Lorlatinib

Category: Cancer



Lorlatinib Overview

Lorlatinib (PF-6463922), sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-neoplastic drug developed by Pfizer. It is an orally-administered small molecule inhibitor of ROS1 and ALK. In 2015, FDA granted Pfizer orphan drug status for lorlatinib for the treatment of non-small cell lung cancer (NSCLC).[1] Lorlatinib is able to cross the blood-brain barrier.[2] Clinical studies Several cli...

Read more Lorlatinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib

Recent Lorlatinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lorlatinib
  • Tablet: 100mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lorlatinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA